Startseite Medizin Precise genome editing with base editors
Artikel Open Access

Precise genome editing with base editors

  • Hongcai Liu , Yao Zhu , Minjie Li und Zhimin Gu ORCID logo EMAIL logo
Veröffentlicht/Copyright: 22. Februar 2023

Abstract

Single-nucleotide variants account for about half of known pathogenic genetic variants in human. Genome editing strategies by reversing pathogenic point mutations with minimum side effects have great therapeutic potential and are now being actively pursued. The emerge of precise and efficient genome editing strategies such as base editing and prime editing provide powerful tools for nucleotide conversion without inducing double-stranded DNA breaks (DSBs), which have shown great potential for curing genetic disorders. A diverse toolkit of base editors has been developed to improve the editing efficiency and accuracy in different context of application. Here, we summarized the evolving of base editors (BEs), their limitations and future perspective of base editing-based therapeutic strategies.

Introduction

The clustered regularly interspaced short palindromic repeats (CRISPR)-associated protein (Cas) system, an adaptive immune system originally found only in bacteria with the capability to direct the silencing of invading nucleic acids [12], has greatly enhanced the toolkit for genome editing. CRISPR gene editing technology has been rapidly applied to precise editing of bacterial [3], plants and mammalian genomes [4]. CRISPR-Cas9 gene editing technology employs artificially designed single guide RNA (sgRNA) to identify targeted DNA sequence in the genome, which guides Cas9 protein to the specific site and cut the DNA helix to generate DNA double strand breaks (DSBs) [5]. DSBs activate two main endogenous cellular repair pathways, non-homologous end joining (NHEJ) and homology-directed repair (HDR) [6], which creates insertions and deletions (indels) or accurate site-specific repairmen, respectively [6]. However, the DSBs most often generates undesired mutations such as indels, translocations, large deletion and chromothrypsis, which can lead to serious consequences such as cancer development [6].

Table 1:

CBE with various characteristics.

Name Deaminase Cas nuclease PAM UGI NLS Editing window References
BE1 rAPOBEC1 dCas9 NGG 4–8 [7]
BE2 rAPOBEC1 dCas9 NGG 4–8 [7]
BE3 rAPOBEC1 nCas9 (H840A) NGG 4–8 [7]
Target-AID PmCDA1 dCas9 NGG 3–7 [8]
AIDx hAIDx dCas9 NGG 5–9 [9]
dCas9-AIDx hAIDx dCas9 NGG 5–9 [9]
CRISPR-X hAIDΔ-MS2 dCas9 NGG −50–50 [10]
ZF-AID hAID ZF NGG [11]
TALE-AID hAID TALE [11]
YE1-BE3 rAPOBEC1-YE1 nCas9 (H840A) NGG 4–7 [12]
YE2-BE3 rAPOBEC1-YE2 nCas9 (H840A) NGG 5–6 [12]
EE-BE3 rAPOBEC1-EE nCas9 (H840A) NGG 5–6 [12]
YEE-BE3 rAPOBEC1-YEE nCas9 (H840A) NGG 5–6 [12]
VQR-BE3 rAPOBEC1 nVQRCas9 (H840A) NGAN 4–11 [12]
EQR-BE3 rAPOBEC1 nEQRCas9 (H840A) NGAG 4–11 [12]
VRER-BE3 rAPOBEC1 nVRERCas9 (H840A) NGCG 3–10 [12]
SaBE3 rAPOBEC1 nSaCas9 (H840A) NNGRRT 3–12 [12]
SaKKH-BE3 rAPOBEC1 nSaKKHCas9 (H840A) NNNRRT 3–12 [12]
PBE rAPOBEC1 nCas9 (D10A) NGG 3–9 [13]
HF2-BE2 rAPOBEC1 HF2-dCas9 NGG 4–8 [14]
HF-BE3 rAPOBEC1 HF1-nCas9 (H840A) NGG 4–8 [15]
eBE-S3 rAPOBEC1 nCas9 (H840A) NGG 4–8 [16]
CDA1-BE3 PmCDA1 nCas9 (D10A) NGG 1×  4–8 [17]
AID-BE3 hAID nCas9 (D10A) NGG 4–8 [17]
APOBEC3G-BE3 hAPOBEC3G nCas9 (D10A) NGG 4–8 [17]
BE3B rAPOBEC1 nCas9 (D10A) NGG 4–8 [17]
SSB-BE3 rAPOBEC1 nCas9 (D10A) NGG 4–8 [17]
N-UGI-BE3 rAPOBEC1 nCas9 (D10A) NGG 4–8 [17]
BE3-2 × UGI rAPOBEC1 nCas9 (D10A) NGG 4–8 [17]
BE3C rAPOBEC1 nCas9 (D10A) NGG 4–8 [17]
BE3D rAPOBEC1 nCas9 (D10A) NGG 4–8 [17]
BE3E rAPOBEC1 nCas9 (D10A) NGG 4–8 [17]
BE4 rAPOBEC1 nCas9 (D10A) NGG 4–8 [17]
SaBE4 rAPOBEC1 nSaCas9 (D10A) NNGRRT 3–12 [17]
BE3-Gam rAPOBEC1 nCas9 (D10A) NGG 4–8 [17]
SaBE3-Gam rAPOBEC1 nSaCas9 (D10A) NNGRRT 3–12 [17]
BE4-Gam rAPOBEC1 nCas9 (D10A) NGG 4–8 [17]
SaBE4-Gam rAPOBEC1 nSaCas9 (D10A) NNGRRT 3–12 [17]
xBE3 rAPOBEC1 nxCas9 (D10A) NG 4–8 [18]
dCpf1-eBE rAPOBEC1 dCpf1 TTTV 8–13 [19]
eAID-BE4max hAID nCas9 (D10A) NGG 4–8 [20]
Spy-macnCas9-BE3 rAPOBEC1 Spy-macnCas9 (D10A) NAA 4–8 [21]
BE-PLUS rAPOBEC11-scFV nCas9 (D10A) NGG 4–16 [22]
eA3A-BE3 hAPOBEC3G-N57G nCas9 (D10A) NGG 4–8 [23]
eA3A-HF1-BE3-2 × UGI hAPOBEC3G-N57G HF1-nCas9 (D10A) NGG 4–8 [23]
eA3A-Hypa-BE3-2 × UGI hAPOBEC3G-N57G nHypaCas9 (D10A) NGG 4–8 [23]
hA3A-BE3 hAPOBEC3A nCas9 (D10A) NGG 2–13 [24]
hA3A-BE3-Y130F hAPOBEC3A-Y130F nCas9 (D10A) NGG 3–8 [24]
Target-AID-NG PmCDA1 nCas9 (D10A)-NG NG 2–8 [25]
BE3-NG rAPOBEC1 nCas9 (D10A)-NG NG 4–8 [25]
A3A-PBE hAPOBEC3A nCas9 (D10A) NGG 1–17 [26]
BE4-max rAPOBEC1 nCas9 (D10A) NGG 4–8 [26]
AncBE4-max rAPOBEC1 nCas9 (D10A) NGG 4–8 [26]
FNLS-BE3 rAPOBEC1 nCas9 (D10A) NGG 3–8 [26]
DBE-A3A hAPOBEC3A-MS2 nCas9 (D10A) NGG 2–17 [27]
DBE-AIDmomo hAID-momo-MS2 nCas9 (D10A) NGG 2–17 [27]
BE3-PAPAPAP rAPOBEC1 nCas9 (D10A) NGG 5–6 [28]
nCDA1-BE3 PmCDA1Δ nCas9 (D10A) NGG 3–4 [28]
enAsBE1.1–1.4 rAPOBEC1 denAsCas12a TTTV 1 × -4× 5–25 [29]
BE3-R33A rAPOBEC1-R33A nCas9 (D10A) NGG 5–7 [30]
BE3-R33A/K34A rAPOBEC1-R33A/K34A nCas9 (D10A) NGG 5–6 [30]
CP-CBEmax rAPOBEC1 CP-nCas9 (D10A) NGG 4–11 [31]
BE3W90Y/R126E rAPOBEC1-W90Y/R126E nCas9 (D10A) NGG 4–8 [32]
hA3A-BE3R128A hAPOBEC3A-R128A nCas9 (D10A) NGG 3–9 [32]
hA3A-BE3Y130F hAPOBEC3A-Y130F nCas9(D10A) NGG 3–9 [32]
evoAPOBEC1-BE4max rAPOBEC1 nCas9(D10A) NGG 3–8 [33]
evoFERNY-BE4max FERNY nCas9 (D10A) NGG 1–8 [33]
evoCDA1-BE4max PmCDA1 nCas9 (D10A) NGG 1–13 [33]
N-1-BE PmCDA1L1_4 (1) nCas9 (D10A) NGG 9–13 [34]
C-1-BE PmCDA1L1_4 (1) nCas9 (D10A) NGG 10–13 [34]
N-2-BE LpCDA1 (2) nCas9 (D10A) NGG 1–8 [34]
C-2-BE LpCDA1 (2) nCas9 (D10A) NGG −1,3–5 [34]
N-4-BE LjCDA1L1_4 (4) nCas9 (D10A) NGG −1–13 [34]
N-7-BE LjCDA1 (7) nCas9 (D10A) NGG 2–6 [34]
N-8-BE LpCDA1L1_1 (8) nCas9 (D10A) NGG 1–14 [34]
C-8-BE LpCDA1L1_1 (8) nCas9 (D10A) NGG 9–14 [34]
N-9-BE LjCDA1L1_1 (9) nCas9 (D10A) NGG 1–15 [34]
N-10-BE LpCDA1L1_3 (10) nCas9 (D10A) NGG 1–13 [34]
N-12-BE LjCDA1L2_1 (12) nCas9 (D10A) NGG 7–12 [34]
N-13-BE LpCDA1L1_4 (13) nCas9 (D10A) NGG 1–12 [34]
BE-PIGS rAPOBEC1 nCas9 (D10A) NGG 4–14 [35]
STEME-1 hAPOBEC3A-ecTadA-ecTadA7.10 nCas9 (D10A) NGG 1–17 [36]
STEME-2 ecTadA-ecTadA7.10-hAPOBEC3A nCas9 (D10A) NGG 1–17 [36]
STEME-3 hAPOBEC3A-ecTadA-ecTadA7.10 nCas9 (D10A) NGG 1–17 [36]
STEME-4 ecTadA-ecTadA7.10-hAPOBEC3A nCas9 (D10A) NGG 1–17 [36]
STEME-NG hAPOBEC3A-ecTadA-ecTadA7.10 nCas9-NG (D10A) NG 1–17 [36]
A3A-PBE-NG hAPOBEC3A nCas9-NG (D10A) NG 1–17 [36]
YE1-BE4 rAPOBEC1-YE1 nCas9 (D10A) NGG 4–7 [37]
YE2-BE4 rAPOBEC1-YE2 nCas9 (D10A) NGG 5–6 [37]
EE-BE4 rAPOBEC1-EE nCas9 (D10A) NGG 5–6 [37]
YEE-BE4 rAPOBEC1-YEE nCas9 (D10A) NGG 5–6 [37]
R33A-BE4 rAPOBEC1-R33A nCas9 (D10A) NGG 5–7 [37]
R33A+ K34A-BE4 rAPOBEC1-R33A/K34A nCas9 (D10A) NGG 5–6 [37]
eA3A-BE4 hAPOBEC3G-N57G nCas9 (D10A) NGG 4–9 [37]
A3A-BE4 hAPOBEC3A nCas9 (D10A) NGG 3–11 [37]
AID-BE4 hAID nCas9 (D10A) NGG 4–8 [37]
CDA-BE4 PmCDA1 nCas9 (D10A) NGG 1–13 [37]
FERNY-BE4 FERNY nCas9 (D10A) NGG 1–8 [37]
BE4-NG rAPOBEC1 nCas9-NG (D10A) NG 3–14 [37]
YE1-BE4-NG rAPOBEC1-YE1 nCas9-NG (D10A) NG 5–8 [37]
YE2-BE4-NG rAPOBEC1-YE2 nCas9-NG (D10A) NG 5–8 [37]
EE-BE4-NG rAPOBEC1-EE nCas9-NG (D10A) NG 5–8 [37]
YEE-BE4-NG rAPOBEC1-YEE nCas9-NG (D10A) NG 5–8 [37]
R33A+ K34A-BE4-NG rAPOBEC1-R33A/K34A nCas9-NG (D10A) NG 5–8 [37]
YE1-BE4-CP1028 rAPOBEC1-YE1 nCas9 (D10A) NGG 3–12 [37]
YE2-BE4-CP1028 rAPOBEC1-YE2 nCas9 (D10A) NGG 3–12 [37]
EE-BE4-CP1028 rAPOBEC1-EE nCas9 (D10A) NGG 3–12 [37]
YEE-BE4-CP1028 rAPOBEC1-YEE nCas9 (D10A) NGG 5–12 [37]
R33A+ K34A-BE4-CP1028 rAPOBEC1-R33A/K34A nCas9 (D10A) NGG 5–12 [37]
AALN-BE4 rAPOBEC1-R33A/K34A/H122L/D124 N nCas9 (D10A) NGG 3–12 [37]
hyBE4max rAPOBEC1 nCas9 (D10A) NGG 4–12 [38]
hyA3A-BE4max hAPOBEC3A nCas9 (D10A) NGG 3–15 [38]
hyeA3A-BE4max hAPOBEC3G-N57G nCas9 (D10A) NGG 4–15 [38]
Target-ACE PmCDA1-ecTadA7.10 nCas9 (D10A) NGG 4–8 [39]
Target-ACEmax PmCDA1-ecTadA7.10 nCas9 (D10A) NGG 2–9 [39]
Target-AIDmax hAID nCas9 (D10A) NGG 2–9 [39]
ACBEmax rAPOBEC1-ecTadA7.10 nCas9 (D10A) NGG 4–9 [39]
A3G-BE4max hAPOBEC3-CTD nCas9 (D10A) NGG 4–10 [40]
TadCBE TadAa nCas9 (D10A) NGG 3–8 [41]
TadDE TadA-CDS nCas9 (D10A) NGG 3–8 [41]
Td-CGBE TadAa-N46L nCas9 (D10A) NGG 5–6 [42]
Td-CBEs TadAa-N46L nCas9 (D10A) NGG 6–7 [42]
Table 2:

ABE with various characteristics.

Name Deaminase Cas nuclease PAM UGI NLS Editing window References
ABE0.1 TadA nCas9 (D10A) NGG [43]
ABE1.1 TadA nCas9 (D10A) NGG [43]
ABE1.2 TadA* nCas9 (D10A) NGG [43]
ABE2.1 TadA* nCas9 (D10A) NGG [43]
ABE2.9 TadA*-TadA* nCas9 (D10A) NGG [43]
ABE3.1 TadA*-TadA* nCas9 (D10A) NGG [43]
ABE4.3 TadA*-TadA* nCas9 (D10A) NGG [43]
ABE5.1 TadA*-TadA* nCas9 (D10A) NGG [43]
ABE5.3 TadA*-TadA* nCas9 (D10A) NGG [43]
ABE6.3 TadA-TadA* nCas9 (D10A) NGG 4–9 [43]
ABE6.4 TadA-TadA* nCas9 (D10A) NGG 1x 4–9 [43]
ABE7.9 TadA-TadA* nCas9 (D10A) NGG 4–9 [43]
ABE7.10 TadA-TadA* nCas9 (D10A) NGG 4–7 [43]
ABE-P1 TadA-TadA* nCas9 (D10A) NGG 4–10 [44]
ABESa TadA-TadA* Sa-Cas9 (D10A) NNGRRT 6–12 [45]
xABE TadA-TadA* x-nCas9 (D10A) NG 4–7 [18]
SaKKH-ABE TadA-TadA* SaKKH-nCas9 (D10A) NNNRRT 3–14 [46, 47]
PABE-7 TadA-TadA* nCas9 (D10A) NGG 4–8 [48]
ABEmax TadA-TadA* nCas9 (D10A) NGG 4–7 [49]
VQR-ABE TadA-TadA* VQR-nCas9 (D10A) NGA 3–8 [46]
VRER-ABE TadA-TadA* VRER-nCas9 (D10A) NGCG 4–8 [47]
NG-ABEmax TadA-TadA* nCas9-NG (D10A) NG 4–8 [25]
ScCas9-ABE (7.10) TadA-TadA* Sc-nCas9 (D10A) NNGN 4–7 [50]
ABE-NG TadA-TadA* nCas9-NG (D10A) NG 4–7 [51]
ABEmaxAW TadA-E59A-TadA*-V106W nCas9 (D10A) NGG 4–8 [52]
ABEmaxQW TadA-E59Q-TadA*-V106W nCas9 (D10A) NGG 4–8 [52]
SaKKH-ABEmax TadA-TadA* SaKKH-nCas9 (D10A) NNNRRT 4–14 [31]
VQR-ABEmax TadA-TadA* VQR-nCas9 (D10A) NGA 4–8 [31]
VRER-ABEmax TadA-TadA* VRER-nCas9 (D10A) NGCG 4–8 [31]
VRQR-ABEmax TadA-TadA* VRQR-nCas9 (D10A) NGA 4–8 [31]
Sa-ABEmax TadA-TadA* Sa-nCas9 (D10A) NNGRRT 4–14 [31]
SaKKH-ABEmax TadA-TadA* SaKKH-nCas9 (D10A) NNNRRT 4–14 [31]
xABEmax TadA-TadA* x-nCas9 (D10A) NGN 4–6 [31]
CP-ABEmax TadA-TadA* CP-nCas9 (D10A) NGG 4–14 [31]
ABE7.10 F148A TadA-F148A-TadA*-F148A nCas9 (D10A) NGG 5 [32]
miniABEmax TadA* nCas9 (D10A) NGG 4–7 [53]
SECURE-ABEs TadA*-K20A/R21A or TadA*-V82G nCas9 (D10A) NGG 4–7 [53]
ABE-P1S TadA* nCas9 (D10A) NGG 3–12 [54]
ABE-P2S TadA* Sa-nCas9 (D10A) NNGRRT 5–17 [54]
ABE-P5S TadA* SaKKH-nCas9 (D10A) NNNRRT 4–9 [54]
ABE8e TadA* nCas9 (D10A) NGG 4–7 [55]
ABE8s TadA* nCas9 (D10A) NGG 3–10 [56]
ABE9 TadA* nCas9 (D10A) NGG 5–6 [57]
  1. TadA*: mutant TadA.

In 2016 David Liu’s team at Harvard University developed a base editing system that enables precise nucleotide conversion without the need of DNA double-strand breaks [7]. The base editing system fuses cytosine deaminase to CRISPR/dead Cas9 (dCas9). Under the guidance of gRNA, the cytidine base editor (CBE) directly converts cytosine (C) to uracil (U) by deamination without causing DNA double strand break. The following DNA replication further replaces U with thymine (T), resulting C-to-T conversion. Based on this concept, adenine base editor (ABE) that catalyzed adenine (A)-to-T nucleotide conversion were also developed by David Liu’s group [43]. Multiple optimized versions of CBEs and ABEs have been developed to overcome different technical bottlenecks. Here we summarized the development and evolving of the CBE and ABE systems (Tables 1 and 2), limitations and discussed future perspectives of applications.

Cytosine base editor (CBE)

Development of CBE

Although deaminases in nature predominantly act on RNA, apolipoprotein B mRNA editing enzyme, catalyticpolypeptide-like (APOBEC) family retains the capability of deamination on single-stranded DNA (ssDNA). The common characteristic of this class of deaminase is a conserved cytidine deaminase (CDA) domain that can deaminate base C. The resultant U from deaminated of C will be further converted to T through DNA repair and replication, achieving C-to-T conversion [7]. With this concept, in April 2016, David Liu’s laboratory at Harvard University developed the first CBE base editor (BE1) [7], which can directly transform C-to-T without requiring DSBs, HDR or donor DNA rAPOBEC1 and dCas9 which is completely lost its cutting activity. Under the guidance of gRNA and dCas9, BE1 achieved effective C-to-T base transition in vitro (25%–40%) with the active window range from 4th to 8th of sgRNA (PAM is calculated as 21–23). However, the uracil DNA glycosylase (UDG) restricts the editing efficiency of BE1 in mammalian cells as its reverse U-G mismatches to C-G base pair through the base-excision repair (BER) in the cells. To overcome the role of UDG, the second-generation base editor BE2 (rAPOBEC1-XTEN-dCas9-UGI) was developed by fusing uracil DNA glycosylase inhibitor (UGI) to BE1. UGI inhibits the function of UDG both in mammalian cells and bacteria, resulting in efficient C-to-T conversion. The Liu laboratory developed the third-generation base editor BE3 (rAPOBEC1-XTEN-nCas9-UGI) immediate after BE2. BE3 replaces the dCas9 in BE2 with nCas9 (D10A) to nick the non-edited strand, which activated the intracellular mismatch repair (MMR) using the edited strand as template to increase the efficiency of base editing. The results showed that BE3 achieved an average editing efficiency around 37% at the 6 sites in human cells, which is two to six-fold more efficient than BE2.

Adopting a similar strategy, the Akihiko Kondo laboratory at Kobe University in Japan successfully developed Target-AID base editor which combined dCas9 with PmCDA1 deaminase from sea lamprey in August 2016 [8]. The Target-AID base editor achieved C-to-T fixed-point replacement both in yeast and mammalian cells with an efficiency of 80 and 10%, respectively. The editing window of Target-AID base editor is three to five bases surrounding the −18 position upstream of the PAM sequence. Consistently, the editing efficiency of Target-AID base editor was greatly improved when combined with UGI and D10A nickase. In October 2016, the Cas9-AID-P182X (AIDx) was invented by fusing human cytidine deaminase hAID to the C terminus of dCas9 in Chang laboratory at Shanghai Jiao Tong University in China. Paired with sgRNAs, dCas9-AID was recruited to targeted genomic loci to induce deamination of cytidines with an enhancement of editing efficiency by introducing uracil-DNA glycosylase inhibitor [9]. Notably, unlike the dCas9-APOBEC1 fusion, in the absence of UGI, AIDx converted C to all other three bases. AIDx expanded the editing window and created more mutations within and beyond the protospacers when combined with multiple sgRNAs. At the same time, the CRISPR-X was developed by Michael C. Bassik laboratory at Stanford University [10]. CRISPR-X employed MS2 modified sgRNAs to recruit hAID, which allowed larger range editing when combined with multiple sgRNAs.

In addition, to overcome PAM sequence dependency the George Church laboratory at Harvard University developed zinc finger (ZF) and transcription activator-like effectors (TALEs) nucleases-based editing systems, which had lower editing efficiency compared to the above-mentioned base editors [11].

Optimization of CBE

Product purity

In addition to C-to-T conversion, CBEs also have a certain chance to convert C to all other three nucleotides [58], which decreases the product purity. To overcome this, at the same month, David Liu laboratory developed a series of base editors to increase the product purity [17]. They firstly replaced the APOBEC1 deaminase with CDA1, AID or APOBEC3G deaminases to generate CDA1-BE3, AID-BE3 and APOBEC3G-BE3, which improved the editing efficiency. Then they fused 2xUGI to the C terminus of BE3 (BE3-2xUGI) which resulted in large increased in product purity and editing efficiency compared to BE3. They went on to optimize the linkers between BE3 components and generated BE3C, BE3D and BE3E, which further improved product purity and editing efficiency. They finally integrated all these improvements into a single base editor to create BE4 and derived versions (BE3-Gam, SaBE3-Gam, BE4-Gam, and SaBE4-Gam) which all substantially increased product purity and efficiency. Chen Jia laboratory at Shanghai University of Science and Technology optimized the expression of UGI and established eBE-S3 to improve the purity of the edited product in mammalian cells in August 2017 [16].

Editing efficiency

The expression level and localization of the intracellular base editor is key determinant factor for editing efficiency. Liu and coworkers generated efficient base editors BE4max and AncBE4max by enhancing the nuclear localization signals and optimizing the codon sequence [49]. Zafra et al. developed FNLS-BE3 with an average 15-fold improvement in editing efficiency compared to BE3 by increasing the number of NLS, changing the position of NLS, and optimizing the codon sequence of nCas9 to the codon sequence preferred by mammalian cells [26]. Recently, Li Dali laboratory at East China Normal University developed hyBE4max, hyA3A-BE4max and hyeA3A-BE4max with higher editing range and activity (up to 257-fold) by fusing a single-stranded DNA-binding protein domain between Cas9 nickase and deaminase [38].

PAM dependency

CBEs of SpCas9 protein fusions requires PAM sequence, which greatly limits the targeting range of CBE in the genome. To this end, Liu et al. replaced SpCas9 with other Cas variants with different PAM preference, which expanded the editing coverage of the CBE systems [12]. The current fusion of different variants have transformed CBE from PAM of NGG to the corresponding PAM forms such as NGA, NGCG, NNGRRT and NNNRRT. In addition, dCpf1-eBE was developed by fusing rAPOBEC1 to a catalytically inactive version of Lachnospiraceae bacterium Cpf1 to overcome base editors limited by G/C-rich PAM [19]. Kleinstiver et al. engineered an enhanced Acidaminococcus sp. Cas12a variant (enAsCas12a) which overcome the requirement of an extended TTTV PAM [29]. Similarly, Zhou et al. fused Sp-macCas9 with rAPOBEC1 to generate Spy-macnCas9-BE3 which recognized a T-rich PAM sequence [21]. Through phage-assisted evolving, Liu and coworkers invented xBE3 which recognized a broad range of PAM sequences including NG, GAA and GAT [18]. Nishimasu et al. created a SpCas9 variant that recognizes NG but not NGG [25]. The SpCas9-NG variant has increased targeting range, has similar specificity to the wild-type enzyme. Zong et al. fused nCas9 with human APOBEC3A to generate A3A-PBE which converted cytidine to thymidine efficiently in wheat, rice and potato with a 17 nt editing window at all examined sites, independent of sequence context [59].

Editing window

The base editing window of different types of CBE is slightly different and should be chosen accordingly. A large modification window will lead to editing of non-target base C around, which brings potential risk when CBE is used in gene therapy and other fields. Hence, Liu laboratory developed YE1-BE3, YE2-BE3, EE-BE3 and YEE-BE3 base editors through mutating key enzyme activation point of the role of the rAPOBEC1 cytosine deaminase, which narrowed the editing window from 5 nt to 1–2 nt with reduced editing efficiency [12]. A series of nCDA1-BE3 versions established by shortening the carboxyl-terminal sequence of PmCDA1 deaminase ensure the editing efficiency and reducing the active window of editing to 1–2 nt [28]. Using circularly permuted Cas9 variants, the Liu laboratory produced four cytosine base editors with an editing window expanded from 4–5 nucleotides to 8–9 nucleotides [31]. They successively developed phage-assisted continuous evolution of base editors (BE-PACE) to improve its editing efficiency and target sequence compatibility such as evoAPOBEC1-BE4max, evoFERNY-BE4max and evoCDA1-BE4max to illuminate the relationship between deaminase activity, base editing efficiency, editing window width and byproduct formation [33]. Liu et al. developed A3G-BE4max to solve the problem of bystander editing when there were multiple C in the editing window [40]. Keith Joung laboratory at Massachusetts General Hospital developed eA3A-BE3 by strengthening the feature that base editing efficiency depends on the sequence background and generated eA3A-HF1-BE3-2 × UGI and eA3A-Hypa-BE3-2 × UGI [23]. These base editors, with decreased editing activity, further reduced editing of adjacent non-target C.

Jiang et al. fused 10 copies of GCN4 peptide to nCas9 for recruiting scFv-APOBEC-UGI-GB1 to the target sites and developed the BE-PLUS system, which broadened the mutation window of BE3 from 5 nt (4–8) to 13 nt (4–16) [22]. Base editors based on fusion hA3A cytosine deaminase have windows of 14 nt (2–13) and 17 nt (1–17) in mammalian cells and plants, respectively [24, 59]. In November 2018, Liu et al. developed DBE-A3A and DBE-AIDmono which can widen the mutation window to positions 2–17, and rely on the CBE system to achieve antibody affinity maturation in cells cultured in vitro [27]. In addition, Cheng et al. screened 13 divergent CDAs and CDALs to generate NT-CBEs and CT-CBEs, which both had expanded and diversified editing scopes [34]. Wang et al. developed BE-PIGS by embedding the deaminase into the Cas9 PI domain, which significantly expanded the editing scope [35]. More recently, Chen et al. reengineered TadA-8e to Td-CGBE with high efficiency and accurate editing window [42].

Adenine base editor (ABE)

Development of ABE

Although adenine deaminases exist in nature with the capability of converting adenine to inosine, such as Escherichia coli TadA (ecTadA), mouse ADA, human ADAR2 and ADAT2. However, none of them use DNA as substrate and none of them showed editing activity on ssDNA when combined with nCas9 [43]. Based on the success of CBE, researchers have further developed the Adenine Base Editor (ABE) with similar principle of action of CBE. ABE is fused by nCas9 and an evolved adenine deaminase that enables A·T-to-G·C conversion. With the guidance of sgRNA, ABE binds to the target sequence region and deaminates a certain range of adenine (A) into inosine (I), which will be treated as guanine (G) at the DNA level [60], eventually achieving the A-to-G conversion. ecTadA is a tRNA adenine deaminase [61] that converts adenine to inosine in the single-stranded anticodon loop of tRNAArg [6263]. Through seven rounds of evolution, Liu et al. generated variants of ecTadA with the capability of acting on ssDNA. Fourteen mutations (A106V, D108 N, D147Y, E155V, L84F, H123Y, I156F, H36L, R51L, S146C, K157 N, P48A, and R152P) were identified, creating ABE7.10 [43]. ABE7.10 was fused by nCas9 to wild-type TadA and modified TadA* which forms heterodimers. ABE7.10 was shown to introduce A-to-G point mutation with an average editing efficiency of 58% and an editing window of position 4–9 within the protospacer in living cells [43], although some studies showed that wild-type TadA was not necessary [53].

Optimization of ABE

To improve the editing efficiency, minimize bystander editing, scientists further optimized the ABE system by directed evolution of ecTadA, changing the number and position of NLS, expanding the selection range of PAM sequences [58, 64, 65]. ABEmax had improved editing efficiency by increasing the number of NLS without expanding editing window. By changing the position of NLS, PABE-7 was designed to improve editing efficiency [48]. Adenine base editors such as xABE [18], ABE-P5 [4647], VQR-ABE [4647], ABE-P4 [47], and NG-ABE [25] were improved in editing efficiency and editing window by expanding the selection of PAM sequences. The directed evolution of ecTadA also improved the editing efficiency of ABE like ABE8e [55] and reduced bystander editing by narrowing the editing window, such as ABE9 [57].

Cytosine and adenine dual base editor

To maximize the editing capability, Liu et al. used a combination of ABE and SaBE3 to achieve both C to T and A-to-G base editing for the first time [66]. In June 2020, Sakata et al. also developed Target-ACEmax to edit C-T and A-G at the same time by combining cytosine and adenine base editors [39]. They also detected that ABE not only generated A-to-G mutant, but also produce unexpected C-to-T mutation with cytosine deamination activity [67].

By phage assisted continuous evolution for cytidine deaminization, David Liu laboratory developed TadCBE with the highly active deoxyadenosine deaminase Tada-8e. They also generated dual-base editor TadDE that performs equally efficient base editing of cytosine and adenine [41]. By repurposing adenine deaminase TadA-8e for cytosine conversion with introduction of the N46L mutation in TadA-8e, they developed highly specific and efficient C-to-G base editor Td-CGBE [42].

Application and perspectives

Since the development of base editing system, CBE and ABE show tremendous application potential both in basic and translational research, including establishment of various mammalian cell lines, animal modeling, agricultural breeding and disease treatment. Zong et al. at the Chinese Academy of Sciences applied base editing in regenerative rice, wheat and maize plants at frequencies of up to 43.48% [13]. They also fused cytidine deaminase and adenosine deaminase to generate engineered dual base editors STEMEs, including STEME-1, STEME-2, STEME-3, STEME-4 and STEME-NG which introduced de novo mutations and facilitate directed evolution of plant genes [36]. Liang et al. generated a modified high-fidelity version of base editor 2 (HF2-BE2) with 100% biallelic C-to-T editing efficiency in mouse embryos [14].

ABE was used to generate Fah mutation in mice to mimic human type I hereditary tyrosinemia (HTI) [46]. ABE was also used to create rat model of Pompe disease [46], rabbit models of X-linked dilated cardiomyopathy (XLCM), and amyotrophic lateral sclerosis (ALS) [68]. The successful applications indicate that ABEs are powerful tools for gene editing in vivo, providing new tools for the establishment of new models and disease treatment.

For human point mutation diseases, such as sickle cell disease and β-thalassemia, ABE8e successfully created two mutations in the promoter of HBG genes, which increased the expression of fetal hemoglobin [55]. ABE9 corrected missense mutations of COL1A2 gene in autosomal dominant osteogenesis imperfecta, mutations of CARD14 gene in psoriasis, BVES mutations in myotonic dystrophy and KCNA5 mutations in common arrhythmia [57].

The ABE systems were also used for gene optimization in rice. ABE-P1 (ABE7.10), ABE-P4 (VERE-ABE), and ABE-P5 (SaKKH-ABE) successfully completed the A·T-to-G·C transformation without introducing any indels or bystander mutations [44]. Application of PAGE-7 resulted in increased herbicide resistance in wheat and rice, which reduced the time cost of weeding [48].

Although base editing techniques have transformed life sciences and exhibit huge potential for precise treatment of genetic disorders, how to further reduce the mutation window and truly modify genes at a single base resolution without affecting the side sequence will be the future focus of base editing system. The recently developed Prime Editing (PE) systems are more promising in accurate base replacement, short sequence insertion and large DNA deletion with a lower editing efficiency when compared to latest version of base editors in general. Well-tailored base editing tools, complementary to prime editing systems, along with cutting-edge delivery methods hold great potential in precision medicine.


Corresponding author: Zhimin Gu, Institute of Systems Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100005, China; and Suzhou Institute of Systems Medicine, Suzhou 215123, Jiangsu Province, China, E-mail:
Hongcai Liu and Yao Zhu contributed equally to this work.

Funding source: CAMS Innovation Fund for Medical Sciences

Award Identifier / Grant number: 2022-RC180-02

Funding source: CAMS Innovation Fund for Medical Sciences

Award Identifier / Grant number: 2022-I2M-1-024

  1. Research funding: This work was supported by CAMS Innovation Fund for Medical Sciences (CIFMS, 2022-I2M-1–024, 2022-RC180-02 to Z.G.).

  2. Author contributions: All authors have accepted responsibility for the entire content of this manuscript and approved its submission.

  3. Competing interests: Authors state no conflict of interest.

  4. Ethical approval: Not applicable.

References

1. Barrangou, R, Fremaux, C, Deveau, H, Richards, M, Boyaval, P, Moineau, S, et al.. CRISPR provides acquired resistance against viruses in prokaryotes. Science 2007;315:1709–12. https://doi.org/10.1126/science.1138140.Suche in Google Scholar PubMed

2. Deltcheva, E, Chylinski, K, Sharma, CM, Gonzales, K, Chao, Y, Pirzada, ZA, et al.. CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III. Nature 2011;471:602–7. https://doi.org/10.1038/nature09886.Suche in Google Scholar PubMed PubMed Central

3. Jiang, W, Bikard, D, Cox, D, Zhang, F, Marraffini, LA. RNA-guided editing of bacterial genomes using CRISPR-Cas systems. Nat Biotechnol 2013;31:233–9. https://doi.org/10.1038/nbt.2508.Suche in Google Scholar PubMed PubMed Central

4. Cong, L, Ran, FA, Cox, D, Lin, S, Barretto, R, Habib, N, et al.. Multiplex genome engineering using CRISPR/Cas systems. Science 2013;339:819–23. https://doi.org/10.1126/science.1231143.Suche in Google Scholar PubMed PubMed Central

5. Cong, L, Zhang, F. Genome engineering using CRISPR-Cas9 system. Methods Mol Biol 2015;1239:197–217. https://doi.org/10.1007/978-1-4939-1862-1_10.Suche in Google Scholar PubMed

6. Symington, LS, Gautier, J. Double-strand break end resection and repair pathway choice. Annu Rev Genet 2011;45:247–71. https://doi.org/10.1146/annurev-genet-110410-132435.Suche in Google Scholar PubMed

7. Komor, AC, Kim, YB, Packer, MS, Zuris, JA, Liu, DR. Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. Nature 2016;533:420–4. https://doi.org/10.1038/nature17946.Suche in Google Scholar PubMed PubMed Central

8. Nishida, K, Arazoe, T, Yachie, N, Banno, S, Kakimoto, M, Tabata, M, et al.. Targeted nucleotide editing using hybrid prokaryotic and vertebrate adaptive immune systems. Science 2016;353:8729. https://doi.org/10.1126/science.aaf8729.Suche in Google Scholar PubMed

9. Ma, Y, Zhang, J, Yin, W, Zhang, Z, Song, Y, Chang, X. Targeted AID-mediated mutagenesis (TAM) enables efficient genomic diversification in mammalian cells. Nat Methods 2016;13:1029–35. https://doi.org/10.1038/nmeth.4027.Suche in Google Scholar PubMed

10. Hess, GT, Frésard, L, Han, K, Lee, CH, Li, A, Cimprich, KA, et al.. Directed evolution using dCas9-targeted somatic hypermutation in mammalian cells. Nat Methods 2016;13:1036–42. https://doi.org/10.1038/nmeth.4038.Suche in Google Scholar PubMed PubMed Central

11. Yang, L, Briggs, AW, Chew, WL, Mali, P, Guell, M, Aach, J, et al.. Engineering and optimising deaminase fusions for genome editing. Nat Commun 2016;7:13330. https://doi.org/10.1038/ncomms13330.Suche in Google Scholar PubMed PubMed Central

12. Kim, YB, Komor, AC, Levy, JM, Packer, MS, Zhao, KT, Liu, DR. Increasing the genome-targeting scope and precision of base editing with engineered Cas9-cytidine deaminase fusions. Nat Biotechnol 2017;35:371–6. https://doi.org/10.1038/nbt.3803.Suche in Google Scholar PubMed PubMed Central

13. Zong, Y, Wang, Y, Li, C, Zhang, R, Chen, K, Ran, Y, et al.. Precise base editing in rice, wheat and maize with a Cas9-cytidine deaminase fusion. Nat Biotechnol 2017;35:438–40. https://doi.org/10.1038/nbt.3811.Suche in Google Scholar PubMed

14. Liang, P, Sun, H, Sun, Y, Zhang, X, Xie, X, Zhang, J, et al.. Effective gene editing by high-fidelity base editor 2 in mouse zygotes. Protein Cell 2017;8:601–11. https://doi.org/10.1007/s13238-017-0418-2.Suche in Google Scholar PubMed PubMed Central

15. Rees, HA, Komor, AC, Yeh, W-H, Caetano-Lopes, J, Warman, M, Edge, ASB, et al.. Improving the DNA specificity and applicability of base editing through protein engineering and protein delivery. Nat Commun 2017;8:15790. https://doi.org/10.1038/ncomms15790.Suche in Google Scholar PubMed PubMed Central

16. Wang, L, Xue, W, Yan, L, Li, X, Wei, J, Chen, M, et al.. Enhanced base editing by co-expression of free uracil DNA glycosylase inhibitor. Cell Res 2017;27:1289–92. https://doi.org/10.1038/cr.2017.111.Suche in Google Scholar PubMed PubMed Central

17. Komor, AC, Zhao, KT, Packer, MS, Gaudelli, NM, Waterbury, AL, Koblan, LW, et al.. Improved base excision repair inhibition and bacteriophage Mu Gam protein yields C:G-to-T:A base editors with higher efficiency and product purity. Sci Adv 2017;3:eaao4774. https://doi.org/10.1126/sciadv.aao4774.Suche in Google Scholar PubMed PubMed Central

18. Hu, JH, Miller, SM, Geurts, MH, Tang, W, Chen, L, Sun, N, et al.. Evolved Cas9 variants with broad PAM compatibility and high DNA specificity. Nature 2018;556:57–63. https://doi.org/10.1038/nature26155.Suche in Google Scholar PubMed PubMed Central

19. Li, X, Wang, Y, Liu, Y, Yang, B, Wang, X, Wei, J, et al.. Base editing with a Cpf1–cytidine deaminase fusion. Nat Biotechnol 2018;36:324–7. https://doi.org/10.1038/nbt.4102.Suche in Google Scholar PubMed

20. Ren, B, Yan, F, Kuang, Y, Li, N, Zhang, D, Zhou, X, et al.. Improved base editor for efficiently inducing genetic variations in rice with CRISPR/Cas9-Guided hyperactive hAID mutant. Mol Plant 2018;11:623–6. https://doi.org/10.1016/j.molp.2018.01.005.Suche in Google Scholar PubMed

21. Chatterjee, P, Lee, J, Nip, L, Koseki, SRT, Tysinger, E, Sontheimer, EJ, et al.. A Cas9 with PAM recognition for adenine dinucleotides. Nat Commun 2020;11:2474. https://doi.org/10.1038/s41467-020-16117-8.Suche in Google Scholar PubMed PubMed Central

22. Jiang, W, Feng, S, Huang, S, Yu, W, Li, G, Yang, G, et al.. BE-PLUS: a new base editing tool with broadened editing window and enhanced fidelity. Cell Res 2018;28:855–61. https://doi.org/10.1038/s41422-018-0052-4.Suche in Google Scholar PubMed PubMed Central

23. Gehrke, JM, Cervantes, O, Clement, MK, Wu, Y, Zeng, J, Bauer, DE, et al.. An APOBEC3A-Cas9 base editor with minimized bystander and off-target activities. Nat Biotechnol 2018;36:977–82. https://doi.org/10.1038/nbt.4199.Suche in Google Scholar PubMed PubMed Central

24. Wang, X, Li, J, Wang, Y, Yang, B, Wei, J, Wu, J, et al.. Efficient base editing in methylated regions with a human APOBEC3A-Cas9 fusion. Nat Biotechnol 2018;36:946–9. https://doi.org/10.1038/nbt.4198.Suche in Google Scholar PubMed

25. Nishimasu, H, Shi, X, Ishiguro, S, Gao, L, Hirano, S, Okazaki, S, et al.. Engineered CRISPR-Cas9 nuclease with expanded targeting space. Science 2018;361:1259–62. https://doi.org/10.1126/science.aas9129.Suche in Google Scholar PubMed PubMed Central

26. Zafra, MP, Schatoff, EM, Katti, A, Foronda, M, Breinig, M, Schweitzer, AY, et al.. Optimized base editors enable efficient editing in cells, organoids and mice. Nat Biotechnol 2018;36:888–93. https://doi.org/10.1038/nbt.4194.Suche in Google Scholar PubMed PubMed Central

27. Liu, LD, Huang, M, Dai, P, Liu, T, Fan, S, Cheng, X, et al.. Intrinsic nucleotide preference of diversifying base editors guides antibody ex vivo affinity maturation. Cell Rep 2018;25:884–92. https://doi.org/10.1016/j.celrep.2018.09.090.Suche in Google Scholar PubMed

28. Tan, J, Zhang, F, Karcher, D, Bock, R. Engineering of high-precision base editors for site-specific single nucleotide replacement. Nat Commun 2019;10:439. https://doi.org/10.1038/s41467-018-08034-8.Suche in Google Scholar PubMed PubMed Central

29. Kleinstiver, BP, Sousa, AA, Walton, RT, Tak, YE, Hsu, JY, Clement, K, et al.. Engineered CRISPR–Cas12a variants with increased activities and improved targeting ranges for gene, epigenetic and base editing. Nat Biotechnol 2019;37:276–82. https://doi.org/10.1038/s41587-018-0011-0.Suche in Google Scholar PubMed PubMed Central

30. Grünewald, J, Zhou, R, Garcia, SP, Iyer, S, Lareau, CA, Aryee, MJ, et al.. Transcriptome-wide off-target RNA editing induced by CRISPR-guided DNA base editors. Nature 2019;569:433–7. https://doi.org/10.1038/s41586-019-1161-z.Suche in Google Scholar PubMed PubMed Central

31. Huang, TP, Zhao, KT, Miller, SM, Gaudelli, NM, Oakes, BL, Fellmann, C, et al.. Circularly permuted and PAM-modified Cas9 variants broaden the targeting scope of base editors. Nat Biotechnol 2019;37:626–31. https://doi.org/10.1038/s41587-019-0134-y.Suche in Google Scholar PubMed PubMed Central

32. Zhou, C, Sun, Y, Yan, R, Liu, Y, Zuo, E, Gu, C, et al.. Off-target RNA mutation induced by DNA base editing and its elimination by mutagenesis. Nature 2019;571:275–8. https://doi.org/10.1038/s41586-019-1314-0.Suche in Google Scholar PubMed

33. Thuronyi, BW, Koblan, LW, Levy, JM, Yeh, W-H, Zheng, C, Newby, GA, et al.. Continuous evolution of base editors with expanded target compatibility and improved activity. Nat Biotechnol 2019;37:1070–9. https://doi.org/10.1038/s41587-019-0193-0.Suche in Google Scholar PubMed PubMed Central

34. Cheng, T-L, Li, S, Yuan, B, Wang, X, Zhou, W, Qiu, Z. Expanding C–T base editing toolkit with diversified cytidine deaminases. Nat Commun 2019;10:3612. https://doi.org/10.1038/s41467-019-11562-6.Suche in Google Scholar PubMed PubMed Central

35. Wang, Y, Zhou, L, Liu, N, Yao, S. BE-PIGS: a base-editing tool with deaminases inlaid into Cas9 PI domain significantly expanded the editing scope. Signal Transduct Targeted Ther 2019;4:36. https://doi.org/10.1038/s41392-019-0072-7.Suche in Google Scholar PubMed PubMed Central

36. Li, C, Zhang, R, Meng, X, Chen, S, Zong, Y, Lu, C, et al.. Targeted, random mutagenesis of plant genes with dual cytosine and adenine base editors. Nat Biotechnol 2020;38:875–82. https://doi.org/10.1038/s41587-019-0393-7.Suche in Google Scholar PubMed

37. Doman, JL, Raguram, A, Newby, GA, Liu, DR. Evaluation and minimization of Cas9-independent off-target DNA editing by cytosine base editors. Nat Biotechnol 2020;38:620–8. https://doi.org/10.1038/s41587-020-0414-6.Suche in Google Scholar PubMed PubMed Central

38. Zhang, X, Chen, L, Zhu, B, Wang, L, Chen, C, Hong, M, et al.. Increasing the efficiency and targeting range of cytidine base editors through fusion of a single-stranded DNA-binding protein domain. Nat Cell Biol 2020;22:740–50. https://doi.org/10.1038/s41556-020-0518-8.Suche in Google Scholar PubMed

39. Sakata, RC, Ishiguro, S, Mori, H, Tanaka, M, Tatsuno, K, Ueda, H, et al.. Base editors for simultaneous introduction of C-to-T and A-to-G mutations. Nat Biotechnol 2020;38:865–9. https://doi.org/10.1038/s41587-020-0509-0.Suche in Google Scholar PubMed

40. Liu, Z, Chen, S, Shan, H, Jia, Y, Chen, M, Song, Y, et al.. Precise base editing with CC context-specificity using engineered human APOBEC3G-nCas9 fusions. BMC Biol 2020;18:111. https://doi.org/10.1186/s12915-020-00849-6.Suche in Google Scholar PubMed PubMed Central

41. Neugebauer, ME, Hsu, A, Arbab, M, Krasnow, NA, McElroy, AN, Pandey, S, et al.. Evolution of an adenine base editor into a small, efficient cytosine base editor with low off-target activity. Nat Biotechnol 2022;1–13.10.1038/s41587-022-01533-6Suche in Google Scholar PubMed

42. Chen, L, Zhu, B, Ru, G, Meng, H, Yan, Y, Hong, M, et al.. Re-engineering the adenine deaminase TadA-8e for efficient and specific CRISPR-based cytosine base editing. Nat Biotechnol 2022;1–10. https://doi.org/10.1038/s41587-022-01532-7.Suche in Google Scholar PubMed

43. Gaudelli, NM, Komor, AC, Rees, HA, Packer, MS, Badran, AH, Bryson, DI, et al.. Programmable base editing of A•T to G•C in genomic DNA without DNA cleavage. Nature 2017;551:464–71. https://doi.org/10.1038/nature24644.Suche in Google Scholar PubMed PubMed Central

44. Hua, K, Tao, X, Yuan, F, Wang, D, Zhu, JK. Precise A·T to G·C base editing in the rice genome. Mol Plant 2018;11:627–30. https://doi.org/10.1016/j.molp.2018.02.007.Suche in Google Scholar PubMed

45. Ryu, SM, Koo, T, Kim, K, Lim, K, Baek, G, Kim, ST, et al.. Adenine base editing in mouse embryos and an adult mouse model of Duchenne muscular dystrophy. Nat Biotechnol 2018;36:536–9. https://doi.org/10.1038/nbt.4148.Suche in Google Scholar PubMed

46. Yang, L, Zhang, X, Wang, L, Yin, S, Zhu, B, Xie, L, et al.. Increasing targeting scope of adenosine base editors in mouse and rat embryos through fusion of TadA deaminase with Cas9 variants. Protein Cell 2018;9:814–9. https://doi.org/10.1007/s13238-018-0568-x.Suche in Google Scholar PubMed PubMed Central

47. Hua, K, Tao, X, Zhu, JK. Expanding the base editing scope in rice by using Cas9 variants. Plant Biotechnol J 2019;17:499–504. https://doi.org/10.1111/pbi.12993.Suche in Google Scholar PubMed PubMed Central

48. Li, C, Zong, Y, Wang, Y, Jin, S, Zhang, D, Song, Q, et al.. Expanded base editing in rice and wheat using a Cas9-adenosine deaminase fusion. Genome Biol 2018;19:59. https://doi.org/10.1186/s13059-018-1443-z.Suche in Google Scholar PubMed PubMed Central

49. Koblan, LW, Doman, JL, Wilson, C, Levy, JM, Tay, T, Newby, GA, et al.. Improving cytidine and adenine base editors by expression optimization and ancestral reconstruction. Nat Biotechnol 2018;36:843–6. https://doi.org/10.1038/nbt.4172.Suche in Google Scholar PubMed PubMed Central

50. Chatterjee, P, Jakimo, N, Jacobson, JM. Minimal PAM specificity of a highly similar SpCas9 ortholog. Sci Adv 2018;4:0766. https://doi.org/10.1126/sciadv.aau0766.Suche in Google Scholar PubMed PubMed Central

51. Hua, K, Tao, X, Han, P, Wang, R, Zhu, JK. Genome engineering in rice using Cas9 variants that recognize NG PAM sequences. Mol Plant 2019;12:1003–14. https://doi.org/10.1016/j.molp.2019.03.009.Suche in Google Scholar PubMed

52. Rees, HA, Wilson, C, Doman, JL, Liu, DR. Analysis and minimization of cellular RNA editing by DNA adenine base editors. Sci Adv 2019;5:5717. https://doi.org/10.1126/sciadv.aax5717.Suche in Google Scholar PubMed PubMed Central

53. Grünewald, J, Zhou, R, Iyer, S, Lareau, CA, Garcia, SP, Aryee, MJ, et al.. CRISPR DNA base editors with reduced RNA off-target and self-editing activities. Nat Biotechnol 2019;37:1041–8. https://doi.org/10.1038/s41587-019-0236-6.Suche in Google Scholar PubMed PubMed Central

54. Hua, K, Tao, X, Liang, W, Zhang, Z, Gou, R, Zhu, JK. Simplified adenine base editors improve adenine base editing efficiency in rice. Plant Biotechnol J 2020;18:770–8. https://doi.org/10.1111/pbi.13244.Suche in Google Scholar PubMed PubMed Central

55. Richter, MF, Zhao, KT, Eton, E, Lapinaite, A, Newby, GA, Thuronyi, BW, et al.. Phage-assisted evolution of an adenine base editor with improved Cas domain compatibility and activity. Nat Biotechnol 2020;38:883–91. https://doi.org/10.1038/s41587-020-0453-z.Suche in Google Scholar PubMed PubMed Central

56. Gaudelli, NM, Lam, DK, Rees, HA, Solá-Esteves, NM, Barrera, LA, Born, DA, et al.. Directed evolution of adenine base editors with increased activity and therapeutic application. Nat Biotechnol 2020;38:892–900. https://doi.org/10.1038/s41587-020-0491-6.Suche in Google Scholar PubMed

57. Chen, L, Zhang, S, Xue, N, Hong, M, Zhang, X, Zhang, D, et al.. Engineering a precise adenine base editor with minimal bystander editing. Nat Chem Biol 2023;19:101–10. https://doi.org/10.1038/s41589-022-01163-8.Suche in Google Scholar PubMed

58. Rees, HA, Liu, DR. Base editing: precision chemistry on the genome and transcriptome of living cells. Nat Rev Genet 2018;19:770–88. https://doi.org/10.1038/s41576-018-0059-1.Suche in Google Scholar PubMed PubMed Central

59. Zong, Y, Song, Q, Li, C, Jin, S, Zhang, D, Wang, Y, et al.. Efficient C-to-T base editing in plants using a fusion of nCas9 and human APOBEC3A. Nat Biotechnol 2018;36:950–3. https://doi.org/10.1038/nbt.4261.Suche in Google Scholar PubMed

60. Yasui, M, Suenaga, E, Koyama, N, Masutani, C, Hanaoka, F, Gruz, P, et al.. Miscoding properties of 2’-deoxyinosine, a nitric oxide-derived DNA Adduct, during translesion synthesis catalyzed by human DNA polymerases. J Mol Biol 2008;377:1015–23. https://doi.org/10.1016/j.jmb.2008.01.033.Suche in Google Scholar PubMed

61. Kim, J, Malashkevich, V, Roday, S, Lisbin, M, Schramm, VL, Almo, SC. Structural and kinetic characterization of Escherichia coli TadA, the wobble-specific tRNA deaminase. Biochemistry 2006;45:6407–16. https://doi.org/10.1021/bi0522394.Suche in Google Scholar PubMed

62. Macbeth, MR, Schubert, HL, Vandemark, AP, Lingam, AT, Hill, CP, Bass, BL. Inositol hexakisphosphate is bound in the ADAR2 core and required for RNA editing. Science 2005;309:1534–9. https://doi.org/10.1126/science.1113150.Suche in Google Scholar PubMed PubMed Central

63. Grunebaum, E, Cohen, A, Roifman, CM. Recent advances in understanding and managing adenosine deaminase and purine nucleoside phosphorylase deficiencies. Curr Opin Allergy Clin Immunol 2013;13:630–8. https://doi.org/10.1097/aci.0000000000000006.Suche in Google Scholar

64. Molla, KA, Yang, Y. CRISPR/Cas-Mediated base editing: technical considerations and practical applications. Trends Biotechnol 2019;37:1121–42. https://doi.org/10.1016/j.tibtech.2019.03.008.Suche in Google Scholar PubMed

65. Yang, B, Yang, L, Chen, J. Development and application of base editors. Crispr J 2019;2:91–104. https://doi.org/10.1089/crispr.2019.0001.Suche in Google Scholar PubMed

66. Liu, Z, Lu, Z, Yang, G, Huang, S, Li, G, Feng, S, et al.. Efficient generation of mouse models of human diseases via ABE- and BE-mediated base editing. Nat Commun 2018;9:2338. https://doi.org/10.1038/s41467-018-04768-7.Suche in Google Scholar PubMed PubMed Central

67. Kim, HS, Jeong, YK, Hur, JK, Kim, J-S, Bae, S. Adenine base editors catalyze cytosine conversions in human cells. Nat Biotechnol 2019;37:1145–8. https://doi.org/10.1038/s41587-019-0254-4.Suche in Google Scholar PubMed

68. Liu, Z, Chen, M, Chen, S, Deng, J, Song, Y, Lai, L, et al.. Highly efficient RNA-guided base editing in rabbit. Nat Commun 2018;9:2717. https://doi.org/10.1038/s41467-018-05232-2.Suche in Google Scholar PubMed PubMed Central

Received: 2022-12-08
Accepted: 2023-02-01
Published Online: 2023-02-22
Published in Print: 2023-02-23

© 2023 the author(s), published by De Gruyter, Berlin/Boston

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Heruntergeladen am 8.12.2025 von https://www.degruyterbrill.com/document/doi/10.1515/mr-2022-0044/html?lang=de
Button zum nach oben scrollen